Progress of preoperative chemoradiotherapy in adenocarcinoma of esophagogastric junctionand mid-distal gastric cancer
10.3760/cma.j.issn.0254-5098.2020.10.013
- VernacularTitle:胃食管结合部腺癌与中远端胃癌术前同步放化疗研究进展
- Author:
Jinming SHI
1
;
Wenyang LIU
;
Jing JIN
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院放疗科 100021
- From:
Chinese Journal of Radiological Medicine and Protection
2020;40(10):802-806
- CountryChina
- Language:Chinese
-
Abstract:
In China, gastric cancer ranks in the second place in morbidity. Patients were mostly diagnosed as an advanced stage at the first time. Radical resection rate was low and the recurrence rate remained high by surgery alone, which resulted in a poor prognosis. Preoperative chemoradiotherapy served as a local therapy method played an important role in gastric cancer gradually. In recent years, although most patients′ tumor are located at the mid-distal gastric cancer, due to the changes of living habits, the number of patients with gastroesophageal junction adenocarcinoma has gradually increased, and their prognosis are relatively poorer compared with the mid-distal gastric cancer.Large-scale phase III studies have confirmed that preoperative radiotherapy and chemotherapy can improve the rate of downstaging and local control in adenocarcinoma of the gastroesophageal junction. However, mid-distal gastric cancer still lacks phase III evidence and more clinical studies are needed to explore the value of preoperative chemoradiotherapy. This review summarizes the progress of preoperative chemoradiotherapy in adenocarcinoma of esophagogastric junction and mid-distal gastric cancer separately.
